Information Provided By:
Fly News Breaks for November 13, 2018
ALKS
Nov 13, 2018 | 07:43 EDT
Leerink analyst Marc Goodman started Alkermes with a Market Perform and $36 price target as he initiates Neuroscience space with a Positive View. The analyst believes the Neuroscience sector is experiencing a "renaissance" as multiple new agents and mechanisms are coming up the pipeline across major therapeutic areas, the number of clinical studies is growing nicely, and the FDA is friendly to innovation in this space, companies are getting smarter about speed-to-market strategies and selecting niche sub-populations to focus on for initial product approvals, payer pushback on usage is much lower than in other categories, and physicians are enthusiastic about new agents. Regarding Alkermes, Goodman believes ALKS-5461 will be stopped by the company based on its mixed efficacy data, opioid concerns, and most importantly, the negative feedback from the FDA's AdCom. Additionally, he believes that expectations are too high for ALKS3831.
News For ALKS From the Last 2 Days
There are no results for your query ALKS